Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
AssigneeDynavax Technologies Corporation
InventorsGary Van Nest, Joseph J. Eiden JR.
Life of this patent
Estimating the term…
Abstract
Methods are provided for the treatment of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. A polynucleotide comprising an immunostimulatory sequence is administered to a individual who has been exposed to or infected by HBV and/or HCV. The polynucleotide is not administered with a HCV or HBV antigen. Administration of the polynucleotide results in amelioration of symptoms of HBV and/or HCV infection.
Claims20
A method of reducing viremia in an individual infected with hepatitis B virus (HBV), comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5′-C, G-3′, wherein an HBV antigen is not administered in conjunction with administration of said composition, and wherein said composition is administered in an amount sufficient to reduce HBV viremia.
A method of reducing blood levels of a hepatitis virus antigen in an individual infected with hepatitis B virus (HBV), comprising administering a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS) to said individual, wherein the ISS comprises the sequence 5′-C, G-3′, wherein an HBV antigen is not administered in conjunction with administration of said composition, and wherein said composition is administered in an amount sufficient to reduce blood levels of a hepatitis virus antigen.
A kit for reducing viremia in an individual infected with or exposed to HBV, comprising a composition comprising a polynucleotide comprising an immunostimulatory sequence (ISS), wherein the ISS comprises the sequence 5′-C, G-3′, wherein said kit does not comprise an HBV antigen;
- and wherein the kit comprises instructions for administration of said composition to an individual infected with or exposed to HBV to reduce viremia.
Dependencies are inferred from the claim text.